Long-Acting, Potent Delivery of Combination Antiretroviral Therapy
- 30 April 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Macro Letters
- Vol. 7 (5) , 587-591
Abstract
Antiretroviral therapy (ART) has revolutionized HIV treatment, yet grand challenges remain: (i) short blood and body residence time of the antiviral drugs, (ii) relative poor antiretroviral drug penetrance into key tissue reservoirs of viral infection, namely, the spleen and lymph nodes, and (iii) obstacles in different pharmacokinetics of the necessary combination drugs. We present a novel drug delivery approach that simultaneously overcomes these limitations. We designed albumin–polymer–drug conjugates where albumin ensures long body residence time as well as lymphatic accumulation of the conjugate. The polymer enabled the delivery of combinations of drugs in precise ratios affording potency superior to the individual antiretroviral drugs and strong protection from HIV infection in primary human T cells.Keywords
Funding Information
- Teknologi og Produktion, Det Frie Forskningsr?d (DFF - 4184-00177)
- amfAR, The Foundation for AIDS Research (109328-59-RGRL)
This publication has 34 references indexed in Scilit:
- Development of an oral once-weekly drug delivery system for HIV antiretroviral therapyNature Communications, 2018
- Defining total-body AIDS-virus burden with implications for curative strategiesNature Medicine, 2017
- Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapyAdvanced Drug Delivery Reviews, 2016
- PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individualsNature Medicine, 2016
- Persistent HIV-1 replication maintains the tissue reservoir during therapyNature, 2016
- HIV infection: epidemiology, pathogenesis, treatment, and preventionThe Lancet, 2014
- Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissuesProceedings of the National Academy of Sciences, 2014
- Past, present and future: 30 years of HIV researchNature Reviews Microbiology, 2013
- The design of drugs for HIV and HCVNature Reviews Drug Discovery, 2007
- Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination TherapyThe Journal of Infectious Diseases, 2000